Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human ADCE-D01 in metastatic/unresectable soft tissue sarcoma (ADCElerate 1)
2024-516900-41-00Phase 2Authorised
- Sponsor
- Adcendo
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of ADCE-D01 in soft tissue sarcoma (STS), sponsored by Adcendo. Primary endpoints: Incidence of dose-limiting toxicities (DLTs), Treatment-emergent adverse events (TEAEs) and laboratory changes (Phase 1a/1b) and 5 more. Planned start Apr 2025; status: authorised.
02
Drugs
ADCE-D01
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2024-516900-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516900-41-00.